3 weeks ago
Park Medi World shares eye new peak after strong Q1 results
Park Medi World is a company that runs hospitals.
This week, its shares — pieces of the company that people can buy — went up on three out of four days.
On Monday, the company shared news about its results for the first part of the year, and many people wanted to buy the shares.
On Tuesday, some people sold their shares to take profits, but other buyers stepped in and the shares rose again.
The share price came very close to its highest price ever.
Two financial experts think the shares can keep climbing.
One expert says the shares could reach ₹350, while the other thinks they could reach ₹375.
The company plans to build many more hospital beds in the coming years.
Because the company is growing and making more money, many investors are excited about it.
Park Medi World shares rose on three of four sessions this week, opening at ₹286 and hitting an intraday high of ₹292 on the NSE, near their record high of ₹305.
Strong buying followed the Q1 results 2026 announcement on Monday, with profit-booking on Tuesday before two straight sessions of gains.
Emkay maintains a BUY rating, raising its Jun-27 target price ~7% to ₹375 from ₹350 on 21x Jun-28E EV/EBITDA.
Choice Broking set a long-term target of ₹350, citing plans to expand capacity from 3,960 beds to over 10,000 beds by FY33.
Management plans 1,000 new beds in FY28 across Gorakhpur, Ambala Oncology, Mohali and Rohtak, plus a recently announced acquisition in Zirakpur near its Mohali facility.
- Who
- Park Medi World, a healthcare company, and analysts at Emkay and Choice Broking
- What
- The company's stock traded near its record high after strong Q1 results, with both brokerages issuing bullish price targets
- Where
- On the National Stock Exchange (NSE) in India; expansion focused on North India including Punjab Tricity, Panchkula, Rudrapur and Agra
- When
- This week, following the Q1 results 2026 announcement on Monday
- Why
- Strong quarterly performance and ambitious hospital bed expansion plans drove investor optimism
Key facts
- Record high
- ₹305
- Intraday high
- ₹292
- Opening price
- ₹286
- Emkay target price
- ₹375
- Choice Broking target price
- ₹350
- Q1FY27 revenue growth
- 19% yoy
- Q1FY27 EBITDA growth
- 20% yoy
- Capacity expansion
- 3,960 beds to over 10,000 beds by FY33
Quotes
Emkay Brokerage
An analyst at Emkay brokerage
“"Management plans to expand capacity from 3,960 beds to over 10,000 beds by FY33, creating a long‑term growth runway."”
livemint.com
“"We maintain BUY and revise up our Jun‑27 TP by ~7% to Rs375 from Rs350, based on 21x Jun‑28E EV/EBITDA."”
livemint.com








